Candelaria, M <br/><br/>
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Sep 2007 
 - 1529-38 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>0923-7534 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdm204  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>DNA Methylation<br/>Drug Resistance, Neoplasm<br/>Epigenesis, Genetic<br/>Female<br/>Histone Deacetylases--metabolism<br/>Humans<br/>Hydralazine--administration & dosage<br/>Male<br/>Neoplasms--drug therapy<br/>Valproic Acid--administration & dosage